Susquehanna International Group, LLP Pds Biotechnology Corp Call Options Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$1.63 - $4.11 $44,825 - $113,025	27,500 New	27,500 $44,000
Q2 2024 Aug 15, 2024	BUY	$2.55 - $4.02 $19,635 - $30,953	7,700 Added 32.35%	31,500 $92,000
Q1 2024 May 07, 2024	BUY	$3.85 - $6.59 $91,630 - $156,842	23,800 New	23,800 $94,000
Q3 2023 Nov 14, 2023	BUY	$4.8 - $6.4 $350,400 - $467,200	73,000 Added 91.25%	153,000 $772,000
Q2 2023 Aug 11, 2023	SELL	$5.03 - $9.9 $561,348 - $1.1 Million	-111,600 Reduced 58.25%	80,000 $402,000
Q1 2023 May 16, 2023	SELL	$5.68 - $11.99 $1.01 Million - $2.12 Million	-177,100 Reduced 48.03%	191,600 $1.18 Million
Q4 2022 Feb 14, 2023	BUY	$3.28 - $13.2 $351,616 - $1.42 Million	107,200 Added 40.99%	368,700 $4.87 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $5.79 $56,133 - $109,431	18,900 Added 7.79%	261,500 $777,000
Q2 2022 Aug 15, 2022	BUY	$3.05 - $6.68 $206,180 - $451,568	67,600 Added 38.63%	242,600 $885,000
Q1 2022 May 16, 2022	BUY	$4.78 - $8.43 $605,148 - $1.07 Million	126,600 Added 261.57%	175,000 $1.08 Million
Q4 2021 Feb 14, 2022	SELL	$7.76 - $14.35 $591,312 - $1.09 Million	-76,200 Reduced 61.16%	48,400 $392,000
Q3 2021 Nov 15, 2021	SELL	$9.33 - $17.08 $295,761 - $541,436	-31,700 Reduced 20.28%	124,600 $1.86 Million
Q2 2021 Aug 11, 2021	BUY	$4.35 - $12.86 $679,905 - $2.01 Million	156,300 New	156,300 $1.96 Million
Q2 2019 Aug 14, 2019	SELL	$5.44 - $8.68 $75,072 - $119,784	-13,800 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$6.8 - $10.08 $93,840 - $139,104	13,800 New	13,800 $102,000

4.26M

163K

6.1K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $44.4M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.